Creatine Disorders Panel, Urine
Initial test to diagnose or rule out creatine deficiency syndromes following clinical presentation. Order Creatine Disorders Panel, Serum or Plasma (2002328), simultaneously for proper result interpretation.
Liquid Chromatography-Tandem Mass Spectrometry
New York DOH Approval Status
Transfer 2 mL urine to an ARUP Standard Transport Tube and freeze immediately. (Min: 0.5 mL)
Clinical information is needed for appropriate interpretation. Additional required information includes age, gender, diet (e.g., TPN therapy), drug therapy, and family history. Biochemical Genetics Patient History Form is available on the ARUP Web site at https://www.aruplab.com/patienthistory or by contacting ARUP Client Services.
Ambient: 6 hours; Refrigerated: 24 hours; Frozen: 6 months (Three freeze/thaw cycles are acceptable.)
Refer to report
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.
Laboratory Developed Test (LDT)
82540; 82570; 82542
|Component Test Code*||Component Chart Name||LOINC|
|2002336||Guanidinoacetic acid, Urine||34155-2|
|2002339||Creatine Disorder Urine Interpretation|
- GAA & Creatine
- GAA + Creatine
- Guanidinoacetic Acid + Creatine
- Guanidnoacetic Acid & Creatine